OKYO Pharma Limited (OKYO)


+0.02 (+0.79%)
Symbol OKYO
Price $1.9856
Beta -2.859
Volume Avg. 0.26M
Market Cap 56.033M
Shares () -
52 Week Range 0.92-7.0
1y Target Est -
DCF Unlevered OKYO DCF ->
DCF Levered OKYO LDCF ->
ROE 999.45% Strong Buy
ROA -59.59% Strong Sell
Operating Margin -
Debt / Equity -107.88% Sell
P/E -3.15 Strong Sell
P/B -14.57 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest OKYO news

Dr. Gary S. Jacob Ph.D.
NASDAQ Capital Market

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.